Current and historical daily PE Ratio for Amgen Inc (
BSP:AMGN34
) from 2011 to May 11 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Amgen stock (BSP:AMGN34) PE ratio as of May 11 2024 is 44.31.
More Details
Amgen Inc (BSP:AMGN34) PE Ratio (TTM) Chart
Amgen Inc (BSP:AMGN34) PE Ratio (TTM) Historical Data
View and export this data going back to 2011. Start your Free Trial
Total 1267
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Amgen PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-11 | 46.9 | 2024-03-07 | 21.4 |
| 2024-05-10 | 46.9 | 2024-03-06 | 21.9 |
| 2024-05-09 | 46.9 | 2024-03-05 | 21.8 |
| 2024-05-08 | 45.1 | 2024-03-04 | 21.9 |
| 2024-05-07 | 44.6 | 2024-03-01 | 22.1 |
| 2024-05-06 | 44.4 | 2024-02-29 | 21.9 |
| 2024-05-03 | 45.9 | 2024-02-28 | 22.0 |
| 2024-05-02 | 41.4 | 2024-02-27 | 21.9 |
| 2024-04-30 | 41.6 | 2024-02-26 | 22.8 |
| 2024-04-29 | 41.2 | 2024-02-23 | 22.5 |
| 2024-04-26 | 40.5 | 2024-02-22 | 22.5 |
| 2024-04-25 | 40.5 | 2024-02-21 | 22.2 |
| 2024-04-24 | 40.5 | 2024-02-20 | 22.2 |
| 2024-04-23 | 40.6 | 2024-02-19 | 22.3 |
| 2024-04-22 | 40.6 | 2024-02-16 | 22.6 |
| 2024-04-19 | 40.6 | 2024-02-15 | 22.8 |
| 2024-04-18 | 40.6 | 2024-02-14 | 22.8 |
| 2024-04-17 | 40.6 | 2024-02-13 | 23.1 |
| 2024-04-16 | 40.6 | 2024-02-12 | 23.1 |
| 2024-04-15 | 40.0 | 2024-02-09 | 23.1 |
| 2024-04-12 | 40.0 | 2024-02-08 | 23.3 |
| 2024-04-11 | 40.0 | 2024-02-07 | 23.8 |
| 2024-04-10 | 39.4 | 2024-02-06 | 24.9 |
| 2024-04-09 | 39.3 | 2024-02-05 | 25.5 |
| 2024-04-08 | 39.5 | 2024-02-02 | 25.5 |
| 2024-04-05 | 39.5 | 2024-02-01 | 25.3 |
| 2024-04-04 | 39.5 | 2024-01-31 | 24.7 |
| 2024-04-03 | 41.5 | 2024-01-30 | 24.5 |
| 2024-04-02 | 41.5 | 2024-01-29 | 24.5 |
| 2024-04-01 | 41.5 | 2024-01-26 | 24.3 |
| 2024-03-28 | 41.2 | 2024-01-25 | 24.1 |
| 2024-03-27 | 22.5 | 2024-01-24 | 24.3 |
| 2024-03-26 | 22.4 | 2024-01-23 | 24.3 |
| 2024-03-25 | 22.0 | 2024-01-22 | 24.3 |
| 2024-03-22 | 21.9 | 2024-01-19 | 24.1 |
| 2024-03-21 | 21.9 | 2024-01-18 | 23.9 |
| 2024-03-20 | 21.6 | 2024-01-17 | 23.7 |
| 2024-03-19 | 21.6 | 2024-01-16 | 23.7 |
| 2024-03-18 | 21.9 | 2024-01-15 | 24.3 |
| 2024-03-15 | 21.8 | 2024-01-12 | 23.6 |
| 2024-03-14 | 21.6 | 2024-01-11 | 23.6 |
| 2024-03-13 | 22.0 | 2024-01-10 | 22.7 |
| 2024-03-12 | 21.7 | 2024-01-09 | 23.9 |
| 2024-03-11 | 21.7 | 2024-01-08 | 23.9 |
| 2024-03-08 | 21.8 | 2024-01-05 | 23.7 |
Amgen Inc (BSP:AMGN34) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Amgen Inc
NAICS : 325412
SIC : 2834
ISIN : BRAMGNBDR004
Share Class Description:
BSP:AMGN34: Shs Unsponsored Brazilian Depository Receipt Repr 1 ShCompare
Compare
Traded in other countries / regions
AMGN.USA0R0T.UKAMGN.ArgentinaAMGN34.BrazilAMG N.MexicoAMG.GermanyAMGN.AustriaAMGN.Chile04332.Hong Kong IPO Date
2011-10-31Description
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers